NON SMALL CELL LUNG CANCER NSCLC

This early-phase study tests a new drug called AB598, alone or with other treatments, in about 40 people with advanced solid tumors like lung, bladder, or ovarian cancer. The main goal is to check if the drug is safe and tolerable. Participants must have measurable tumors and be …

This study looks at how well the drug brigatinib works in adults with a specific type of lung cancer (ALK-positive NSCLC). Researchers will track how long the cancer stays under control and how many patients respond to treatment. About 50 people will take brigatinib as part of th…

This study tests whether adding olaparib to durvalumab can keep stage IV non-small cell lung cancer from progressing longer than durvalumab alone. About 400 adults whose cancer did not worsen after initial chemotherapy plus durvalumab will receive either the combination or durval…

This early study tests a new treatment for people with advanced colorectal, pancreatic, or lung cancer that has a specific change in the KRAS gene (called G12V). The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer c…

This study tests a new treatment called RP1, a virus that attacks cancer cells, combined with the immunotherapy drug nivolumab. It includes 340 adults with advanced solid tumors such as melanoma, non-small cell lung cancer, and certain skin cancers. The goal is to see if the comb…

This early-stage study tests an experimental drug called HER3-DXd in people with advanced non-small cell lung cancer (NSCLC) that has stopped responding to other treatments. The goal is to check the drug's safety and see if it can shrink tumors. The study includes patients with d…

This study tests an experimental oral drug called IMM-1-104 in people with advanced solid tumors that have RAS mutations. The goal is to find the best dose and see if it can shrink tumors or slow their growth. About 209 adults with pancreatic cancer, melanoma, or lung cancer will…

This study tests whether combining two targeted drugs, osimertinib and amivantamab, can safely control advanced non-small cell lung cancer with a specific EGFR mutation. About 60 adults who have not had prior treatment for their advanced or metastatic disease will receive the dru…

This study tests whether adding a cholesterol-lowering drug (alirocumab) to an immunotherapy (cemiplimab) can shrink tumors in people with advanced non-small cell lung cancer that has stopped responding to prior immunotherapy. About 60 participants will receive both drugs to see …

This program provides expanded access to cemiplimab, a cancer drug, for people with non-small cell lung cancer, basal cell carcinoma, or cutaneous squamous cell carcinoma who have no other treatment options. The goal is to make the drug available to those who cannot join a clinic…

This program provides access to the drug ceritinib for people with serious ALK-positive tumors or non-small cell lung cancer who have no other treatment options and cannot join a clinical trial. It is only available through a doctor's request and aims to offer potential benefit w…

This program provides early access to telisotuzumab vedotin, an investigational drug, for people with non-small cell lung cancer who have no other suitable treatment options and cannot join ongoing clinical trials. A doctor must decide if the potential benefits outweigh the risks…

This study tested whether adding the immunotherapy drugs durvalumab and tremelimumab to standard chemotherapy helps people with advanced non-small cell lung cancer live longer without their disease getting worse. About 1,200 adults with a specific type of lung cancer that had spr…

This study tests a new drug, MK-2870, against standard chemotherapy for people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation) and has stopped responding to targeted pills. About 520 participants will be randomly assigned to receive either…

This study tests three new drug combinations for people with advanced non-small cell lung cancer that has high PD-L1 levels and has not been treated before. The goal is to see if adding another immunotherapy drug to the standard anti-PD1 treatment can better control the cancer. A…

This early-phase study tests a new drug called RMC-6291 in adults with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to find a safe dose and see how the body handles the drug. About 222 people with lung, colorectal, or pancreatic cancer that has not r…

This study tests a wearable device that creates electric fields (TTFields) combined with the immunotherapy drug pembrolizumab for people with advanced non-small cell lung cancer that has worsened after standard treatments. The goal is to see if this combination helps people live …

This early-phase trial tests two experimental vaccines (ChAdOx1 and MVA) designed to help the immune system attack cancer cells. The vaccines target proteins MAGE-A3 and NY-ESO-1, which are found in some lung and esophageal cancers. About 15 participants will receive the vaccines…

This early-stage study tests an experimental drug called cofetuzumab pelidotin in 65 adults with a specific type of recurrent non-small cell lung cancer (NSCLC) that has a protein called PTK7. The drug is designed to deliver a toxin directly to cancer cells. The main goal is to s…

This study compares a new drug, MK-2870, to standard chemotherapy (docetaxel or pemetrexed) in 556 adults with advanced non-small cell lung cancer that has specific genetic changes (EGFR mutations or others). The goal is to see if MK-2870 can slow cancer growth and help people li…

This early-stage study tests a drug called furmonertinib in 160 people with advanced lung cancer that has certain gene mutations (EGFR or HER2). The goal is to see if the drug is safe and can shrink tumors. Participants have already tried other treatments without success.

This study tests whether combining a targeted drug (osimertinib) with precise radiation (SABR) can help people with advanced EGFR-mutant lung cancer live longer without their disease getting worse. About 41 adults with this specific type of lung cancer will receive both treatment…

This study tests an experimental antibody called GEN1042, alone or with the cancer drug pembrolizumab (with or without chemotherapy), in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The goal is to see if the treatment is safe …

This study looks at how muscle mass, strength, and function relate to treatment side effects, quality of life, and survival in people with lung cancer. Researchers will follow 160 patients to understand why some struggle to complete their cancer therapy. The goal is to find ways …

This study observes 300 adults with advanced non-small cell lung cancer and low PD-L1 levels to see how safe and tolerable their first treatments are. Researchers track side effects, how often they happen, and what healthcare resources are used. The goal is to understand real-wor…

This early-phase study involves 14 adults with advanced head and neck, lung, or skin cancer who have not responded to prior treatments. Researchers use PET/CT scans to see how two experimental antibodies, BI 765063 and BI 770371, travel to tumors when given alongside another immu…

This study compares two ways of taking tissue samples from lung cancer patients to see which method provides better samples for genetic testing. About 349 adults with known or suspected non-small cell lung cancer will be randomly assigned to have a biopsy with or without a cytote…

This study observes 404 adults in Italy with advanced non-small cell lung cancer who are starting treatment with nivolumab plus ipilimumab. Researchers will collect real-world data on how well the treatment works, side effects, and patient characteristics. The goal is to understa…

This study looks at how long Chinese patients with a specific type of advanced lung cancer (ALK-positive NSCLC) stay on the drug brigatinib when it's their first treatment. Researchers will also track how well the drug controls the cancer over time. The study does not give any ne…